Introduction
============

The genetic adaptation of Tibetans to high-altitude environments at the Qinghai-Tibetan plateau (average elevation: 4,000 m) represents a remarkable case of natural selection during recent human evolution ([@msw280-B3]; [@msw280-B49]; [@msw280-B6]). Previous genome-wide scans have identified many candidate genes that may contribute to this adaptation, including two genes (*EPAS1* and *EGLN1*) that are involved in the HIF (hypoxia inducible factor) pathway, which showed the strongest signals of selective sweeps in Tibetans ([@msw280-B2]; [@msw280-B5]; [@msw280-B40]; [@msw280-B53]; [@msw280-B32]; [@msw280-B51]). Both genes harbor sequence variants highly enriched in Tibetans (50--80%), but absent or rare (\<5%) in lowlanders ([@msw280-B32]; [@msw280-B50]; [@msw280-B20]; [@msw280-B27]).

*EPAS1* encodes HIF-2α, and *EGLN1* encodes prolyl 4-hydroxylase 2 (PHD2). Under normoxia, *EGLN1* performs its oxygen-dependent hydroxylase function and triggers degradation of HIF proteins (HIF-1α and HIF-2α). Under hypoxia, the hydroxylase activity of *EGLN1* is suppressed, resulting in the accumulation of HIFs that can transactivate hundreds of downstream target genes and induce diverse physiological responses, for example, erythropoiesis ([@msw280-B19]). It was reported that the Tibetan version of *EGLN1* carries two Tibetan-specific missense mutations ([@msw280-B50]), which cause increased HIF degradation under hypoxia that revokes the HIF-mediated augmentation of erythropoiesis, and protects Tibetans from polycythemia (red cell overproduction) at high altitudes ([@msw280-B27]). Another study showed that the Tibetan *EGLN1* variant might be a loss of function allele, leading to augmented HIF activation to facilitate adaptation to high altitude ([@msw280-B41]). However, how the Tibetan version of *EPAS1* works is still unclear. Unlike *EGLN1* variants, all identified *EPAS1* variants are located in the noncoding regions (mostly in introns), suggesting that they may affect *EPAS1*'s regulation at the transcriptional level ([@msw280-B32]). We conducted a series of experiments to understand the functional effects of the Tibetan-enriched *EPAS1* variants and reveal the underlying molecular mechanism.

Result
======

Identification of *EPAS1* Adaptive Variant Candidates
-----------------------------------------------------

Using published genome data ([@msw280-B32]; [@msw280-B29]), we identified a total of 204 variants across the entire gene region of *EPAS1* (97.0 kb) in Tibetans (refer to the "Material and Methods" section for details), and 180 of them are shared with the lowland reference populations (Han Chinese, Japanese, Europeans and Africans from the 1000 Genomes Project). It is expected that Darwinian positive selection would drive enrichment of the adaptive alleles in Tibetans, but not in lowlanders. To search for functional variants, we chose *EPAS1* variants showing the largest allelic divergence (*F~ST ~*\>0.50) between high-altitude Tibetans and worldwide lowlanders. We obtained 32 *EPAS1* candidate variants for further analysis ([supplementary table S1, Supplementary Material](#sup1){ref-type="supplementary-material"} online), including the recently reported 3.4-kb Tibetan-enriched deletion (TED) 80-kb downstream of *EPAS1* ([@msw280-B28]). The map of linkage disequilibrium (LD) among the 32 candidate variants fits the expectation of an extended Tibetan-specific haplotype resulting from selective sweep ([fig. 1](#msw280-F1){ref-type="fig"}). Notably, TED showed a strong LD with the downstream *EPAS1* SNPs (*D*′ \> 0.85) ([fig. 1](#msw280-F1){ref-type="fig"}). F[ig]{.smallcaps}. 1.Map of linkage disequilibrium among the 32 EPAS1 sequence variants (lower panel) with the largest allelic divergence (*F~ST ~*\> 0.5) between high altitude Tibetans and low altitude populations (upper panel).

To further evaluate the evolutionary and functional roles of the 32 candidate variants, we next conducted two haplotype-based selection tests, the iHS test and the XP-EHH test ([@msw280-B46]; [@msw280-B42]), and the results confirmed that the Tibetan-specific haplotype had undergone a strong selective sweep ([supplementary table S1, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Furthermore, we performed multiple functional predictions, including cross-species sequence conservation (measured by GREP ++), transcription factor binding site (TFBS), splicing motif, H3K4Me1/H3K4Me3 sites and DNAase-I hypersensitive site. The results suggest that many variants are located within the predicted functional elements ([supplementary table S1, Supplementary Material](#sup1){ref-type="supplementary-material"} online). We speculate that there might be multiple functional variants and they form a Tibetan-specific haplotype to regulate *EPAS1*'s transcription. We previously showed that this Tibetan-specific *EPAS1* haplotype was prevalent in Tibetans (72%), rare in Han Chinese (2.2%), and absent in other global populations ([@msw280-B32]).

*EPAS1* Adaptive Allele at rs149594770 Weakens Promoter Activity
----------------------------------------------------------------

Among the 32 candidate variants, we selected one variant (rs149594770) located in a H3K4Me1 peak (peak score = 62.8) with the highest sequence conservation among all tested variants (GERP ++ score = 4.94). The A allele of rs149594770 is prevalent (presumably adaptive) in Tibetans (57.2%), but rare in lowlanders (0.5% in Han Chinese, 3.2% in Africans, and absent in Japanese and Europeans).

We first used EMSA (electrophoretic mobility shift assay) to test if the two alleles at rs149594770 have different transcription factor binding affinity. The result showed that the Tibetan-enriched "A" allele had a weaker binding affinity to Hela nuclear extracts compared with the wild-type "T" allele, and this was further confirmed by the competitor probe assay ([fig. 2*A*](#msw280-F2){ref-type="fig"}). We next tested with the luciferase reporter gene assay using 293T cells, and the results clearly indicated weaker promoter activity of the Tibetan-enriched "A" allele compared with the wild-type "T" allele ([fig. 2*B*](#msw280-F2){ref-type="fig"}). We observed the same pattern when repeating the experiment using Hela cells ([supplementary fig. S1, Supplementary Material](#sup1){ref-type="supplementary-material"} online). As the 32 candidate variants are tightly linked, this result implies that the Tibetan-specific haplotype is likely functional. F[ig]{.smallcaps}. 2.In vitro functional test of the *EPAS1* variant (rs149594770) using an electrophoretic mobility shift assay (*A*) and a luciferase reporter gene assay (*B*). The two-tailed *t* test was used for statistical assessment.

Tibetan-Specific *EPAS1* Haplotype Down-Regulates Expression
------------------------------------------------------------

To reveal the transcriptional regulation of the Tibetan-specific *EPAS1* haplotype, we conducted an in vitro analysis using endothelial cells derived from Tibetan umbilical cords (ECU) because endothelial cells are responsive to hypoxia and selectively express *EPAS1* ([@msw280-B44]). By genotyping a subset (10 variants) of the candidate variants, we were able to obtain three wild-type haplotype homozygotes from 105 Tibetan umbilical cords, and we paired them with three adaptive haplotype homozygotes and conducted tests using a hypoxic assay ([supplementary table S2, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Cells were subject to prolonged hypoxic conditions (1% oxygen) for 7 days and the expression level of *EPAS1* was determined by qPCR at eight time points (0 h, 6 h, 12 h, 1 day, 2 days, 3 days, 5 days and 7 days). As expected the expression of *EPAS1*, being a hypoxia inducible factor, started to rise at Day-2 and kept increasing till Day-7, consistent with previous observations ([@msw280-B19]). Importantly, the adaptive ECU line showed a relatively lower *EPAS1* expression compared with the wild-type ECU line ([fig. 3*A*](#msw280-F3){ref-type="fig"}), which was confirmed by two replicate experiments though the magnitudes varied ([supplementary fig. S2, Supplementary Material](#sup1){ref-type="supplementary-material"} online). When pooling data from all three replicates, we detected a significant down-regulation of the adaptive ECU lines (*P* = 0.0063, one-way ANOVA). On an average, there was a 31.3% reduction of EPAS1 expression in the adaptive ECU lines compared with the wild-type controls over the 7-day period. These results suggest that the *EPAS1* adaptive haplotype down-regulates *EPAS1*'s expression under hypoxic conditions. Consistently, a previous report also observed a decreased *EPAS1* mRNA expression in Tibetan lymphocytes ([@msw280-B33]). F[ig]{.smallcaps}. 3.Changes of *EPAS1* expression in Tibetan umbilical endothelial cells during prolonged hypoxic treatment (*A*) and in term Tibetan placentas (*B*). The adaptive ECU lines are homozygotes of the adaptive *EPAS1* haplotype, and the wildtype ECU lines are homozygotes of the wildtype *EPAS1* haplotype. TIB Hom, Tibetan homozygote; TIB Het, Tibetan heterozygote; Han Hom, Han Chinese homozygote; WT, wild-type. The one-way ANOVA and two-tailed *t* tests were conducted for panel *A* and panel *B*, respectively.

Furthermore, we tested 63 term placenta samples from Tibetans living in Lhasa (elevation: 3,680 m). The fetal section of villus parenchyma was analysed with RNAseq. We classified the Tibetan placenta samples into three haplotype groups, the wild-type haplotype homozygotes (WHH, *n* = 3), the heterozygotes (HET, *n* = 26) and the adaptive haplotype homozygotes (AHH, *n* = 34). Consistent with the results of the endothelial cells, the AHHs showed a significantly lower *EPAS1* expression compared with the WHHs (27.1% reduction on an average), and the HETs fell in between ([fig. 3*B*](#msw280-F3){ref-type="fig"}). In comparison, we also analysed 14 Han Chinese placentas from Kunming of southwestern China (elevation: 1,800 m), and these Han WHHs showed relatively low EPAS1 expression, similar with the Tibetan AHHs and HETs ([fig. 3*B*](#msw280-F3){ref-type="fig"}), indicating that most high-altitude Tibetans have a similar level of *EPAS1* expression in the placenta as the lowlander Han Chinese, a reflection of Tibetans' adaptation at altitude. In addition, the single variant analysis also showed significant association with *EPAS1*'s expression ([supplementary table S3, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Thus, both endothelial cell and placenta data suggest a down-regulation of *EPAS1* expression in Tibetans, which may serve as the molecular basis of adaptation to high-altitude hypoxia.

*EPAS1*+/− Mice Show Blunted Hypoxic Responses
----------------------------------------------

To dissect how *EPAS1*'s down-regulation leads to the adaptive physiological changes in Tibetans, we utilized heterozygous *EPAS1* knockout mice (*EPAS1*+/−) as these mice have ∼50% reduction of intact *EPAS1* transcripts ([@msw280-B8]). It is known that *EPAS1* not only works as a hypoxia inducible factor, but it is also involved in embryonic development because homozygous *EPAS1* knockout mice (*EPAS1*−/−) either died of cardiac failure at mid-gestation or of severe respiratory failure as neonates ([@msw280-B43]; [@msw280-B9]). Interestingly, the *EPAS1*+/− mice were viable and healthy, and they were indistinguishable from their wild-type (WT) littermates under normoxia ([@msw280-B43]). Under long-term severe hypoxia, the *EPAS1*+/− mice performed better than the WT mice, and showed blunted hypoxic responses ([@msw280-B8]).

We conducted the experiment by housing both *EPAS1*+/− and WT mice in a hypoxic chamber (Coy Laboratory Products, MI) and tested their physiological responses to prolonged normobaric hypoxia (4 weeks at 12% O~2~ and 10% O~2~, equivalent to the oxygen levels at ∼4,000 m and ∼5,000 m, respectively). The experiment under normoxia (21% O~2~) was performed as reference. Consistent with the previous data ([@msw280-B8]), under 10% O~2~, the *EPAS1*+/− mice indeed performed better than the WT mice, reflected by less weight loss, lower hemoglobin concentration, lower right ventricle (RV) pressure and less RV hypertrophy (*P* \< 0.05, two-tailed *t* test). Similar differences were also observed under 12% O~2~ though less significant, while no difference was detected under normoxia ([fig. 4](#msw280-F4){ref-type="fig"}). In particular, during prolonged hypoxia, the WT mice experienced vascular remodeling with thick-walled vessels in the lung, but this did not occur in the *EPAS1*+/− mice ([supplementary fig. S2, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Hence, the data indicates that a 50% reduction of *EPAS1* expression causes blunted responses to prolonged hypoxia in the *EPAS1*+/− mice, mirroring the situation in Tibetans. F[ig]{.smallcaps}. 4.In vivo tests of *EPAS1*+/− and WT mice under prolonged hypoxia. (*A*) Weight loss percentage; (*B*) systolic RV pressure; (*C*) degree of RV hypertrophy; and (*D*) hemoglobin concentration. The degree of RV hypertrophy was determined by the weight ratio of right ventricle to heart. Mice were kept in a hypoxic chamber for 4 weeks at two oxygen levels (7 *EPAS1*+/− vs. 6 wild-type mice at 12%, and 6 *EPAS1*+/− vs. 5 wild-type mice at 10%). The data at normoxia (4 *EPAS1*+/− vs. 5 wild-type mice at 21% O~2~) was collected as reference. WT, wild-type mice.

To reveal the underlying molecular mechanisms of the observed physiological changes in mice, we next conducted RNAseq for five types of tissues (lung, heart, liver, kidney, and spleen; six *EPAS1*+/− mice vs. four WT mice at 10% O~2~). As expected, the *EPAS1*+/− mice showed a 53.8--59.7% reduction of intact *EPAS1* transcripts compared with the WT mice in all five tissues, and the highest *EPAS1* expression was observed in the lung ([supplementary fig. S4, Supplementary Material](#sup1){ref-type="supplementary-material"} online). We identified a total of 4,494 differentially expressed genes (DEGs) between *EPAS1*+/− and WT mice in at least one tissue ([supplementary data set S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online), an indication of the large impact of *EPAS1* on downstream gene regulation. Interestingly, most of the DEGs (79.3%) were tissue-specific ([supplementary fig. S5*A*, Supplementary Material](#sup1){ref-type="supplementary-material"} online), suggesting a tissue-differential regulation by *EPAS1*.

The liver and the kidneys have the largest numbers of DEGs (1,997 and 1,523 genes, respectively) ([supplementary table S4, Supplementary Material](#sup1){ref-type="supplementary-material"} online) with functional enrichment in protein transportation, energy metabolism, oxidation--reduction process, heme/iron-ion binding and others, reflecting mostly different transitions from oxidative to glycolytic metabolism under hypoxia between *EPAS1*+/− and WT mice ([@msw280-B38]). The spleen has 880 DEGs ([supplementary table S4, Supplementary Material](#sup1){ref-type="supplementary-material"} online), most of which are involved in immune responses to hypoxia ([@msw280-B30]). Notably, the most significant KEGG pathway in the spleen is hematopoietic cell lineage (adjusted *P* = 2.29e ^−^ ^10^) ([supplementary table S5, Supplementary Material](#sup1){ref-type="supplementary-material"} online), which is consistent with the known role of *EPAS1* in erythropoiesis under hypoxia ([@msw280-B19]). In contrast, the lung and the heart have the least number of DEGs (742 and 520 genes, respectively) with one enriched functional category (extracellular space) for lung and none for heart ([supplementary table S4, Supplementary Material](#sup1){ref-type="supplementary-material"} online).

To further establish the molecular connections between *EPAS1*'s down-regulation and the adaptive physiological changes in the *EPAS1*+/− mice, we checked a set of 473 gene candidates with known functions in hypoxic responses and/or related to the physiological traits ([@msw280-B40]; [@msw280-B29]). Of those, 127 genes (26.8%) were DEGs ([supplementary table S6, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Similar with the aforementioned pattern, most of the DEGs (78.0%) were tissue-specific ([supplementary fig. S5*B*, Supplementary Material](#sup1){ref-type="supplementary-material"} online). As a known target gene of *EPAS1* and a negative mediator of *EPAS1*-regulated genes, HIF-3α showed a consistent down-regulation across all tissues (3.3-to 6.8-fold reduction) ([supplementary table S7, Supplementary Material](#sup1){ref-type="supplementary-material"} online), which may help fine-tune the overall hypoxic responses of the *EPAS1*+/− mice under hypoxia ([@msw280-B17]).

In the regulation of erythropoiesis, the kidney serves as the most important oxygen sensor and responds to systemic hypoxia with a rapid increase in erythropoietin (EPO) production by renal interstitial fibroblast-like cells, and *EPAS1* is the main regulator of hypoxic EPO induction ([@msw280-B15]). Although we observed a significantly lower Hb level in the *EPAS1*+/− mice than that in the WT mice ([fig. 4*D*](#msw280-F4){ref-type="fig"}), we did not detect an EPO expression difference in the kidneys (*P* \> 0.05, two-tailed *t* test). This was likely caused by the observed low expression of EPO (0--2.18 TPM in the kidney and none in other tissues) as the kidney samples for RNAseq probably only contained a small number of EPO-producing renal cells. We measured EPO concentration (at protein level) in the blood, and we observed a higher EPO level in the WT mice compared with the *EPAS1*+/− mice under hypoxia, consistent with the pattern of *EPAS1* expression difference. No EPO level difference was detected under normoxia ([supplementary fig. S6*A*, Supplementary Material](#sup1){ref-type="supplementary-material"} online).

Notably, *ACE* (angiotensin I converting enzyme), a key blood pressure regulator was significantly down regulated in the lungs and the heart (33% and 66% reductions, respectively) ([supplementary table S7, Supplementary Material](#sup1){ref-type="supplementary-material"} online). This explains the relatively low pulmonary arterial pressure (PAP, measured as RV pressure) and less RV hypertrophy of the *EPAS1*+/− mice since the *ACE* knockout mice displayed a low blood pressure ([@msw280-B24]), and increased cardiac ACE augments cardiac hypertrophy ([@msw280-B45]). In contrast, the kidneys showed an up-regulation of *ACE*, which could be explained by the reported independent effects of ACE on maintenance of normal blood pressure and renal functions ([@msw280-B23]). Consistently, *VEGFC* (vascular endothelial growth factor C), a gene involved in chronic hypoxic pulmonary hypertension ([@msw280-B31]) was also down regulated in the lungs (62% reduction) ([supplementary table S7, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Additionally, a recent study showed that the vasodilatory apelin (a vasodilatory peptide encoded by *APLN*) signaling was down regulated in the PHD2 (encoded by *EGLN1*) deficient mice ([@msw280-B22]). In the *EPAS*+/− mice, we observed significant up-regulation of *APLN* (logFC = −0.771, *P* = 2.32e-4) compared with the wild-type mice, implying that the vasodilatory apelin signaling may also contribute to the observed low pulmonary pressure of the *EPAS1*+/− mice under prolonged hypoxia.

Finally, two nitric oxide synthases (iNOS and eNOS, also called NOS2 and NOS3) were differentially expressed with an up-regulation of iNOS in the heart and a down-regulation of eNOS in the lungs, the liver and the kidneys ([supplementary table S7, Supplementary Material](#sup1){ref-type="supplementary-material"} online). In mice, both iNOS and eNOS are the target genes of *EPAS1* and they produce nitric oxide (NO), an important vasodilator ([@msw280-B18]). We measured the blood NO concentration and we did not see difference between the *EPAS1*+/− and WT mice (*P* \> 0.05, two-tailed *t* test) either under normoxia or under hypoxia ([supplementary fig. S6*B*, Supplementary Material](#sup1){ref-type="supplementary-material"} online), which seems to contradict the previous observation that high-altitude Tibetans had much higher levels of blood NO levels compared with lowlanders ([@msw280-B14]).

High-Altitude Tibetans Have Similar Placenta Expression Profiles as Lowlander Han Chinese
-----------------------------------------------------------------------------------------

The placenta is the key organ of maternal--fetal oxygen exchange, and *EPAS1* is highly expressed in the placenta as an important gene for fetal development ([@msw280-B43]). We analysed the transcriptomes of 63 high altitude Tibetan and 14 low altitude Han Chinese term placentas. As aforementioned, the 63 Tibetan placentas were classified into three groups based on their *EPAS1* haplotypes (3 WHHs, 26 HETs and 34 AHHs). We first compared the Tibetan AHHs with the Han controls. Only 276 DEGs (135 up-regulated and 141 down-regulated) were identified and no enriched functional categories or pathways were detected ([supplementary table S8, Supplementary Material](#sup1){ref-type="supplementary-material"} online). When using a stringent statistical cutoff (corrected *P* \< 0.01), no DEGs remained. We also compared the Tibetan HETs with the Han controls, and no DEGs were identified, nor in the comparison between the Tibetan AHHs and HETs. This suggests that high-altitude Tibetans have in general similar placenta transcriptional profiles as lowlander Han Chinese, a reflection of adaptation at altitude. Due to the small sample size of the Tibetan WHHs (*n* = 3), they were excluded from the analysis.

*EPAS1* Variants Are Associated with Multiple Physiological Traits of Tibetans
------------------------------------------------------------------------------

We conducted a survey of physiological traits among 508 unrelated Tibetan individuals from Bange of Tibet (elevation: 4,700 m) to test whether the *EPAS1* variants are responsible for the known adaptive traits of Tibetans. We measured three physiological parameters, including the Hb concentration, the systolic pulmonary arterial pressure (PAP) and the degree of blood oxygen saturation (SaO~2~). As expected, males had a higher Hb level compared with females. We also observed a between-sex difference for SaO~2~, but not for PAP ([supplementary fig. S7, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Because the elevation at Bange is among the highest altitude regions in Tibet with permanent residents, we observed a relatively large portion of Tibetans showing high Hb (≥ 200 g/l, 23.4% in males and 4.8% in females) and PAP (≥ 30 mmHg, 43.9% in males and 54.7% in females), which implied that even for Tibetans, an elevation of 4,700 m might be a big challenge.

We genotyped five EPAS1 variants (rs149594770, rs370299814, rs73926265, rs1888801636 and TED) in the 508 Tibetans. As a reference, we also genotyped two *EGLN1* variants (rs186996510 and rs12097901). The result of association is listed in [table 1](#msw280-T1){ref-type="table"}. Consistent with previous observations ([@msw280-B2]; [@msw280-B53]; [@msw280-B32]; [@msw280-B50]), all tested variants were significantly associated with the hemoglobin levels in Tibetans. On an average, each *EPAS1* variant could explain 2.87% variance of Hb, and the percentages were 1.91% for TED and 1.44% for the two *EGLN1* variants ([table 1](#msw280-T1){ref-type="table"}). For example, the adaptive alleles of rs149594770 and rs73926265 accounted for 6.15 and 12.65 g/l deductions of hemoglobin levels, respectively ([supplementary fig. S8, Supplementary Material](#sup1){ref-type="supplementary-material"} online). This result suggests that the Tibetan versions of *EPAS1* and *EGLN1* contribute to the relatively low Hb level of high-altitude Tibetans. Table 1.Results of Genetic Association Analysis of Three Physiological Traits in Bange Tibetans.TraitGeneSNP IDMale (*n*=219)Female (*n*=289)All (*n*=508)BetaEMP′BetaEMP′BetaEMP″*R*^2^ (%)**HbEGLN1**rs12097901−12.192.8E-04−4.110.07−7.418.9E-052.11rs186996510−5.950.02−2.050.27−3.790.020.77**EPAS1**rs149594770−4.400.06−3.720.03−4.046.7E-031.40rs370299814−5.270.04−2.600.20−3.800.021.33rs73926265−10.821.9E-04−8.009.0E-04−9.471.0E-064.93rs188801636−8.444.3E-03−7.909.7E-03−8.141.2E-043.83**/**TED−4.880.08−5.198.0E-03−5.041.2E-031.91**PAPEGLN1**rs12097901−1.300.48−0.530.70−0.770.440.23rs1869965101.110.46−1.590.19−0.590.750.27**EPAS1**rs1495947701.360.44−2.836.5E-03−1.200.120.68rs3702998141.300.42−1.370.24−0.320.860.11rs73926265−0.320.86−3.080.03−1.990.040.99rs188801636−0.410.86−2.210.18−1.330.410.20**/**TED1.740.20−0.360.640.410.860.08**SaO~2~EGLN1**rs12097901−0.340.75−0.290.86−0.290.460.05rs1869965100.480.590.051.000.270.560.17**EPAS1**rs149594770−0.920.070.260.86−0.270.560.09rs370299814−1.140.07−0.700.15−0.890.040.87rs73926265−1.270.050.090.86−0.610.260.33rs188801636−1.010.17−0.070.86−0.580.320.50**/**TED−0.790.270.240.75−0.220.520.05[^3]

We observed a significant association of two *EPAS1* variants (rs149594770 and rs73926265) with PAP (corrected *P* \<0.05) ([table 1](#msw280-T1){ref-type="table"}). The adaptive alleles tended to have a lower PAP compared with the wild-type alleles ([supplementary fig. S9, Supplementary Material](#sup1){ref-type="supplementary-material"} online), explaining the well-known low hypoxic pulmonary vasoconstriction response in Tibetans ([@msw280-B49]). Compared with Hb, there was less PAP variance explained by the *EPAS1* variants (e.g., 0.68% by rs149594770 and 0.99% by rs73926265) ([table 1](#msw280-T1){ref-type="table"}).

Lastly, we observed a weak association of one *EPAS1* variant (rs370299814, corrected *P* = 0.04) with SaO~2~. But the presumably adaptive allele (enriched in Tibetans) at rs370299814 showed a lower SaO~2~ level compared with the wild-type allele ([supplementary fig. S10, Supplementary Material](#sup1){ref-type="supplementary-material"} online). The same trend was observed for the other *EPAS1* variants including TED although it was statistically not significant (corrected *P* \> 0.05) ([table 1](#msw280-T1){ref-type="table"}). This result implies that *EPAS1* may not be the gene contributing to the reported better SaO~2~ of Tibetans compared with Han newcomers at altitude ([@msw280-B3]; [@msw280-B49]).

Discussion
==========

When lowlanders stay at high altitudes, hypobaric hypoxia induces erythropoiesis, mainly triggered by the accumulation of HIF-2α and the downstream transactivation of EPO production. The prolonged exposure of lowlanders to hypobaric hypoxia usually leads to overproduction of red cells (polycythemia), which increases the risk of heart attack, stroke, and fetal loss during pregnancy ([@msw280-B38]). In contrast, Tibetans are genetically protected from polycythemia. It was speculated that the Tibetan genotype associated with absence of an erythrocytotic response to hypoxia may encode reduced HIF-2α activity along with other alterations that increase metabolic efficiency ([@msw280-B38]). Here, we provided evidence that the functional change of *EPAS1* as an adaptive strategy for hypoxia occurred at the transcription level, where the *EPAS1* adaptive variants caused a reduced *EPAS1* expression under hypoxia compared with the wild-type controls. Based on the data from Tibetan endothelial cells and placentas, the reduced levels of *EPAS1* expression were 31.3% and 27.1%, respectively, a significant reduction that serves as the molecular basis for blunted hypoxic responses in Tibetans. It should be noted that in the reporter gene assay, there was over a 10-fold reduction of promoter activity with the Tibetan-enriched "A" allele of rs149594770. Although the trend is the same as those in human endothelial cells and placentas, this magnitude may not reflect the in vivo situation as 293T and Hela cells were used.

Although both HIF-1α and HIF-2α can induce EPO production during hypoxia, HIF-2α is dominant in renal EPO-regulation, as HIF-2α expression in the kidney co-localizes with EPO-producing renal cells ([@msw280-B15]). This regulation mechanism explains why the *EPAS1* adaptive variants have the greatest impact on Hb among the tested physiological parameters in Tibetans ([table 1](#msw280-T1){ref-type="table"}). Accordingly, the *EPAS1*+/− mice (50% reduction) showed a similar Hb regulation with Tibetans ([fig. 4](#msw280-F4){ref-type="fig"}). Interestingly, *EGLN1*, the other key adaptive gene has a similar strategy as *EPAS1* does, but works at the post-translational level. The Tibetan version of *EGLN1* carries two amino acid mutations ([@msw280-B50]), resulting in a stronger enzyme activity and an increased degradation of HIFs under hypoxic conditions ([@msw280-B27]). Taken together, current evidence suggests that the Tibetan versions of *EPAS1* and *EGLN1* push toward the same direction for blunted responses to hypoxia ([@msw280-B6]), and they both reduce the amount of HIF-2α in Tibetans under hypoxic conditions---one at transcriptional level and the other at post-translational level---leading to a decreased HIF-mediated augmentation of erythropoiesis that protects Tibetans from high-altitude polycythemia ([@msw280-B27]).

Besides a relatively low hemoglobin level, Tibetans also exhibit other adaptive traits, including sustained high resting-ventilation, low hypoxic pulmonary vasoconstriction response and better arterial oxygen saturation ([@msw280-B49]). We showed that two *EPAS1* variants were significantly associated with a low PAP in Tibetans ([table 1](#msw280-T1){ref-type="table"}). The mouse data provided a possible molecular mechanism of how *EPAS1* affects hypoxic pulmonary vasoconstriction response. We observed a significant down-regulation of *ACE* and *VEGFC* in the heart and the lungs of the *EPAS1*+/− mice compared with the WT mice ([supplementary table S7, Supplementary Material](#sup1){ref-type="supplementary-material"} online). Being a key regulator of normal blood pressure, *ACE* generates the vasoconstricting peptide angiotensin II and inactivates the vasodilating peptide bradykinin ([@msw280-B13]). *ACE* knockout mice exhibit low blood pressure ([@msw280-B24]), and over-expression of ACE augments cardiac hypertrophy in transgenic rats ([@msw280-B45]). *VEGF* is a target gene of *EPAS1* and plays an important role in angiogenesis. In rats, the up-regulation of *VEGF* is involved in vascular remodeling associated with the development of pulmonary hypertension ([@msw280-B31]). Hence, the mouse data suggest that the Tibetan version of *EPAS1* likely contributes to low PAP of Tibetans through a down-regulation of *ACE* and *VEGFC*.

Both iNOS and eNOS are the target genes of *EPAS1*, and they produce NO, an important molecule for vasodilation ([@msw280-B10]; [@msw280-B37]). It was reported that in comparison to sea level controls, Tibetans had \>10-fold-higher circulating concentrations of bioactive NO products ([@msw280-B14]), which may explain the improved blood flow and low PAP in Tibetans. However, in mice, iNOS and eNOS showed an opposite pattern with an up-regulation of iNOS and a down-regulation of eNOS in the *EPAS1*+/− mice. We did not detect a blood NO concentration difference between the *EPAS1*+/− mice and the WT mice. The observed higher blood NO concentration of high-altitude Tibetans could be caused merely by altitude difference because the previous report did not test NO levels in lowlanders living at high altitude, nor in Tibetans living at sea level ([@msw280-B14]). Thus, further experiments are required to determine if NO plays a role in blood flow and pulmonary vasoconstriction response of Tibetans.

The Tibetan versions of *EPAS1* and *EGLN1* do not seem to account for the reported better SaO~2~ in Tibetans compared with Han new comers at altitude ([@msw280-B49]), although a major autosomal dominant gene was previously inferred to explain the difference of the SaO~2~ levels in Tibetan women ([@msw280-B3]). Current evidence suggests that Tibetans have a better SaO~2~ level than lowlander Han Chinese during submaximal and maximal exercise, but no difference was detected at rest ([@msw280-B48]). In this study, we measured SaO~2~ of Tibetans at rest, and we observed a weak negative association. Hence, whether SaO~2~ serves as one of the adaptive traits of Tibetans and what gene is responsible remains unanswered.

In view of fetal development, although the *EPAS1* expression reduction can cause regulatory changes in many downstream genes, it may not have a great impact on placenta and fetal development. We observed similar transcriptional profiles in the placentas of high-altitude Tibetans and lowlander Han Chinese. Also, the *EPAS1*+/− mice with a 50% expression reduction turned out to be developmentally normal ([@msw280-B43]). Alternatively, since the oxygen exchange of the developing fetus depends on maternal blood circulation, the genetic background of the mother instead of the fetus is presumably more influential to fetal development as previous data showed that Tibetan women with high oxygen saturation had more surviving children than women with low oxygen saturation ([@msw280-B3]).

Finally, Tibetans are likely the earliest human populations who adapted to high altitude environments because their permanent settlement in the Qinghai-Tibetan plateau was dated as early as 30,000 years ago based on genetic data ([@msw280-B39]; [@msw280-B35]). Previous studies indicated that the onset of *EPAS1* and *EGLN1* selection occurred at different times, ∼18,000 years ago for *EPAS1* and ∼8,000 years ago for *EGLN1*, which coincide the two proposed migratory waves into Qinghai-Tibetan Plateau during Upper Paleolithic and early Neolithic times ([@msw280-B35]). Regardless of whether the Tibetan version of EPAS1 was introduced by introgression from archaic humans ([@msw280-B20]), the selection on *EPAS1* likely represents the initial Paleolithic adaptation of Tibetan ancestors at altitude, and the Tibetan version of *EGLN1* was probably introduced later during early Neolithic due to the expansion of the earliest Neolithic agriculturalists who originated in the Upper Yellow River basin of China ∼8,500 years ago ([@msw280-B35]). This two-episode selection model accounts for the prevalence of the adaptive versions of *EPAS1* and *EGLN1* in current Tibetan populations.

Materials and Methods
=====================

Collection of Physiological Data and Blood Samples of Tibetans
--------------------------------------------------------------

Physiological data and blood samples were collected from unrelated Tibetans permanently residing at Bange county of Nagqu prefecture (*n* = 508, 219 males and 289 females, 37.41 ± 3.8 years old) with an elevation 4,700 m. Biologically related individuals were excluded from this study. Written informed consents for all participants were obtained. For physiological parameters, we collected hemoglobin concentration (Hb), level of arterial oxygen saturation (SaO~2~) and systolic pulmonary artery pressure (PAP), which are among the key adaptive physiological traits in Tibetans ([@msw280-B49]). Hb was measured using a HemoCue Hb 201+ analyzer (Angelholm, Sweden). SaO~2~ was measured at forefinger tip with a hand-held pulse oximeter (Nellcor NPB-40, CA) at rest, and the fingertip was cleaned with alcohol swab before measurement. Venous blood was collected from each individual for Hb measurement and DNA extraction. For echocardiographic measurements, standard parasternal, apical, and subcostal two-dimensional views and color flow-directed pulsed wave Doppler of transvalvular flows and continuous wave Doppler of the tricuspid regurgitant jet flow were performed on fully rested subjects in the supine or left lateral decubitus position using a portable ultrasound system (Vivid I, GE Healthcare) equipped with a 1.5--3.6 MHz M4S-RS matrix sector array transducer. The peak systolic tricuspid regurgitation pressure gradient (TRPG) as an estimate of the systolic pulmonary artery pressure was calculated using the simplified Bernoulli equation: TRPG = 4 × TRVmax2, where TRVmax is the maximal velocity of the tricuspid regurgitant jet. All measurements were made in triplicates, and results are presented as means and the studies were evaluated blindly as to the source of individual recordings. The protocol of this study was approved by the Institutional Review Board of the Kunming Institute of Zoology, Chinese Academy of Sciences.

Selection of Candidate *EPAS1* Variants
---------------------------------------

We analysed the entire 93-kb gene region of *EPAS1*. The 3.4-kb deletion (TED) 80-kb downstream of *EPAS1* was also included. A total of 83 unrelated Tibetan individuals were analysed with 50 of them from the genome-wide SNP data (by Affymetrix Genome-wide Human SNP Array 6.0) ([@msw280-B32]) and 33 of them from genome sequencing (by Illumina HiSeq X10) ([@msw280-B29]). Among the 83 unrelated Tibetans, we identified a total of 204 *EPAS1* sequence variants. After compared with four lowlander populations from the 1000 Genomes Project, including 103 Han Chinese from Beijing (CHB), 104 Japanese (JPT), 99 Europeans (CEU) and 108 Africans (YRI) (<http://www.1000genomes.org>), we obtained 180 *EPAS1* shared variants for further analysis.

Locus specific *F~ST~* was calculated between Tibetans and the four lowlander populations following the previous method ([@msw280-B47]). We also calculated the *F~ST~* value of TED (Tibetan enriched deletion) by treating TED as a bi-allelic variant.

For iHS and XP-EHH tests, due to the high rate of missing genotype in the genome array data, we only used the genome sequencing data (30× genome coverage) of the 33 unrelated Tibetan individuals ([@msw280-B29]). The missing genotypes were rare (0.92%) and retrieved by imputation. The iHS scores were calculated for all variants using Selscan ([@msw280-B42]) based on the phased haplotypes. Phasing was conducted using Beagle 4.1 ([@msw280-B7]), and only loci whose ancestral alleles were known with certainty and a minor allele frequency (MAF) ≥ 0.05 were included in the analysis ([@msw280-B46]). The XP-EHH analysis was used to detect the extended haplotypes resulting from positive selection in Tibetans ([@msw280-B36]). We computed XP-EHH scores using Selscan ([@msw280-B42]) based on the phased haplotypes of Tibetans and CHB (as the reference population). The XP-EHH score at each SNP was standardized by the mean XP-EHH and the standard deviation over the genome. An absolute iHS or XP-EHH value of \>2.0 is considered a signal of selection.

For functional prediction of the candidate *EPAS1* variants, we measured the conservation score for each variant using GERP (Genome Evolutionary Rate Profiling) (<http://mendel.stanford.edu/SidowLab/downloads/gerp/>). The GERP ++ method was used ([@msw280-B54]) to calculate site-specific RS scores and to discover evolutionarily constrained elements. Positive scores represent a substitution deficit (i.e., fewer substitutions than the average neutral site) and thus indicate that a site may be under evolutionary constraint. Positive scores scale with the level of constraint, such that the greater the score, the greater the level of evolutionary constraint inferred to be acting on that site. Negative scores indicate that a site is probably evolving neutrally. For calculating the GERP value of TED, we took the average of the entire 3.4 kb (3,400 sites) region.

Functional enrichment analysis of the candidate variants was conducted using CADD (Combined Annotation Dependent Depletion) (<http://krishna.gs.washington.edu/download/CADD/v1.3/>1000[G_phase3_inclAnno.tsv.gz](http://G_phase3_inclAnno.tsv.gz)), which contains a list of 114 annotation categories for all variants in 1000G Phase 3. Five annotation categories were used in this study, including maximum ENCODE H3K4 methylation level (EncH3K4Me1), maximum ENCODE H3K4 trimethylation level (EncH3K4Me3), *P* value (PHRED-scale) of DNase I hypersensitivity evidence for open chromatin (EncOCDNasePVal), number of different overlapping ChIP transcription factor binding sites (TFBS), and ACCEPTOR or DONOR of the closest splice site (Dst2SplType). The H3K4Me1 value indicates the maximum ENCODE H3K4 methylation level (the maximum value observed across the 16 ENCODE cell lines at a given position), where modification of histone proteins is suggestive of enhancer and, to a lesser extent, other regulatory activity. The H3K4Me3 value indicates the maximum ENCODE H3K4 trimethylation level (the maximum value observed across the 16 ENCODE cell lines at a given position), where modification of histone proteins is suggestive of promoters. The DNase I hypersensitivity track indicates where chromatin is hypersensitive to cutting by the DNase enzyme, which has been assayed in a large number of cell types. Regulatory regions tend to be DNase-sensitive, and promoters are particularly DNase-sensitive. Dnase P indicates *P* value (PHRED-scale) of Dnase evidence for open chromatin. The transcription factor binding site (TFBS) is indicated by the number of different overlapping ChIP transcription factor binding sites ([supplementary table S1, Supplementary Material](#sup1){ref-type="supplementary-material"} online). In addition, Splice indicates that the closest splice site of the tested variant is either ACCEPTOR or DONOR ([supplementary table S1, Supplementary Material](#sup1){ref-type="supplementary-material"} online).

Endothelial Cell Hypoxic Assay
------------------------------

Tibetan umbilical cords were obtained from 105 normal, full-term pregnancies at the People's Hospital of Lhasa, Tibetan Autonomous Region of China. Written informed consent was obtained from each subject. The human umbilical vein endothelial cells (HUVECs) were isolated from the veins of umbilical cord by the well-established method ([@msw280-B21]). In brief, cords were separated from placentas within 2 h after delivery. The umbilical vein was cannulated and washed through with sterile phosphate buffered saline (PBS), supplemented with 100 units/ml penicillin, 0.1 mg/ml streptomycin and 5.6 µg/ml amphotericin B in order to remove any blood clots. It was then infused with 1 mg/ml (125 U/ml) of type I collagenase (Gibco) in Ca2+ and Mg2+ free PBS, and incubated at 37 °C for 15 min. After incubation, the HUVECs were flushed from the vein vessel together with the collagenase solution. The obtained HUVECs were cultured on flasks coated with 1% gelatin. The cells were grown in complete medium (Medium199 supplemented with 10% FBS, 20 mmol/l HEPES (pH 7.4), 1 ng/ml recombinant human fibroblast growth factor (bFGF), 1 ng/ml endothelial growth factors (EGF), and 100 units/ml penicillin, 0.1 mg/ml streptomycin) (Gibco) at 37ºC in 5% CO~2~, and the medium was changed every 2--3 days. About 7∼10 days, the primary culture cells were confluent in the flask. For subculture, cells were detached and harvested with 0.05% trypsin-EDTA solution, then neutralized with FBS (Gibco). When the cells were cultured to passage-3, they were cryopreserved with cell freezing medium (NCS + 10% DMSO) in liquid nitrogen.

All hypoxia experiments were performed in passage-5 cells. The HUVECs were divided into two groups (adaptive vs. nonadaptive *EPAS1* haplotype). We conducted three paired experiments, that is, ECU-A01 versus ECu-W01, ECU-A02 versus ECU-W02, and ECU-A03 versus ECU-W03. Each cell line has two replication dishes. Cells were placed in a conventional 37 °C humidified incubator (Thermo-Forma, Model 3141) with automated gas control of 1% O~2~, 5% CO~2~, balanced with N~2~. The oxygen concentration of the hypoxic incubator was constantly monitored by a real-time O~2~ sensor with 0.1% sensitivity. Cells were harvested at different time points, including 0 h, 6 h, 12 h, 24 h (1 day), 48 h (2 days), 72 h (3 days), 120 h (5 days) and 168 h (7 days). For each dish, three parallel quantitative real-time PCR were performed to determine the expression level of *EPAS1*, therefore, there are six data points for each cell line.

RNAseq Data Generation and Analysis
-----------------------------------

Paired-end reads were generated from Illumina HiSeq 2500 platform. We followed a previous protocol to remove low quality reads ([@msw280-B52]), where reads with adapters or with \>10% ambiguous bases or with \>50% low quality bases (Q-score ≤ 5) were removed. On an average, we generated 24.5 million paired-end reads for each sample. The RNAseq data was deposited in an open-access archive (Genome Sequence Achieve at <http://gsa.big.ac.cn>) and the accession numbers are PRJCA000268 and PRJCA000269.

Pre-processed RNA-Seq reads were mapped to the genome using split-mapping aligner STAR (release 2.4.1a) ([@msw280-B12]), and the resulting bam files were feed to RSEM (version 1.2.11) ([@msw280-B26]) to estimate gene expression abundance. To handle reads mapped to multiple locations, RSEM takes mapping uncertainty into account with a generative model and the EM algorithm to achieve accurate abundance estimates at both the isoform and gene levels ([@msw280-B26]). The mouse genome sequence was downloaded from Ensembl (release 81) ([@msw280-B11]), and the human genome was downloaded from Gencode release 19 ([@msw280-B16]). To detect differentially expressed genes, we used a python framework HTSeq ([@msw280-B1]) to count the number of reads mapped to each gene, and then applied the *voom* method embedded in the R package *limma* ([@msw280-B25]), which is a Bayesian method accounting for mean--variance relationship. Genes with multiple test corrected *P* value \<0.05 were determined as differentially expressed.

Since the second exon of *EPAS1* is replaced by a nonmouse-origin frame-shifting sequence in the *EPAS1* knockout copy, it might be possible that the inactivated transcript decays quickly and cannot be detected, leading to similar expression levels across all exons. To explore this possibility, we inspected the number of reads mapped to exon2 of *EPAS1* and its flanking exon1 and exon3 in both knockout and wildtype mice, and found similar expression level of exon1 and exon3 as well as a clear reduction of reads mapped to exon2 in knockout mice compared with wildtype, indicating the inactivated transcript retains to be measured. Moreover, we noticed that the estimate of active *EPAS1* transcripts would be biased if we include reads mapped to inactivated copies. To correct this, we counted reads mapped to exon1, 2 and 3 of *EPAS1*, and calculated the average ratio of exon2/exon1 and exon2/exon3 for each sample, the adjusted *EPAS1* expression estimate is then obtained by multiplying the ratio with the uncorrected estimate.

Electrophoretic Mobility Shift Assay and Luciferase Reporter Assay
------------------------------------------------------------------

To test the predicted functional of SNP rs149594770, we performed electrophoretic mobility shift assay (EMSA). The double-stranded probes were obtained through boiling and gradual cooling of the complementary single-strand oligonucleotides. The nucleotide sequences of the double-stranded oligonucleotides with either T or A allele are:

T allele: 5′-TCTTTAGGGTGAGCTGACCTTTCCAGATGGAGCAGGGAAAT-3

A allele: 5′-TCTTTAGGGTGAGCTGACCTATCCAGATGGAGCAGGGAAAT-3′.

DNA binding reactions were premixed with a 200-fold molar excess of unlabeled competitors at room temperature for 20 min, followed by another 20 min of incubation when adding the labeled probes. After incubation, samples were separated on a native 6% polyacrylamide gel, and then rapidly transferred to a positive nylon membrane, UV-cross-linked, probed with streptavidin-HRP conjugate and incubated with the substrate.

For luciferase reporter assay, the 100-bp synthetic single-strand oligonucleotides were annealed to form double strands consisting of the corresponding genotypes (TT and AA) for rs149594770 flanked by restriction sites. The fragments were then cloned into the multiple cloning site of the pGL3-promoter vector (Promega). All constructs were validated by sequencing to make sure no *de novo* mutation was introduced. The reporter vectors containing either T allele or A allele were co-transfected into HEK293T and HeLa cells, respectively, together with a reference vector (pRL-TK vector). HeLa and HEK293T cells were grown in Gibco Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% fetal bovine serum (HyClone). Lipofectamine 2000 (Invitrogen) was used in transient transfection. After a 36-h incubation, we collected the cell lysates and measured luciferase activity using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). The relative light units were measured using a luminometer. The mean values of three independent experiments were used.

Prolonged Hypoxic Experiments in Mice
-------------------------------------

Eight-week-old mice (littermates; mixed-background Swiss/129Sv) were weighted and placed in a polycarbonate hypoxic chamber (Coy Laboratory Products). The oxygen level in the chamber is controlled automatically by balancing the air with N~2~. After exposure to prolonged hypoxia for the indicated period, mice were first equilibrated by room air for 1 h in order to avoid acute vasomotor responses, and were then anesthetized with urethane (1.4 mg/g). The closed chest method was used to measure cardiac function. A 1.2-F pressure catheter (Transonic Scisense Inc) was used to measure right ventricle (RV) pressure. RV pressure and heart rate were recorded continuously (MP150, BIOPAC Systems). Arterial blood was collected in heparinized glass capillaries (50 µl) and immediately analysed for hemoglobin (Hb) concentration. Hb concentration was determined using a spectrophotometer (B-Hemoglobin, HemoCue). The degree of RV hypertrophy was determined by the weight ratio of right ventricle to heart.

The measurement of predominant species of NO2− and NO3− in plasma were employed to reveal the level of NO synthesis, and the NO level in plasma is almost all reflected by the level of nitrate because the nitrite level in plasma is only ∼1% of nitrate. We adopted a chemiluminescence method to measure the concentration of NO using a nitric oxide analyzer following the protocol provided by the manufacture (Sievers model 280, GE Analytical Instruments, Boulder, CO). The plasma sample was treated with precooling ethanol (2 folds) to eliminate proteins. The calibration curve was constructed by plotting the peak area versus concentration of the standard NaNO~3~ solution (pre-treated with 2 folds ethanol). Sample injection was carried out using a Hamilton syringe with 5-in long needle, and 30 µl plasma sample was injected for each sample. Two injections were measured for each sample and the average value of the two measurements was taken. To eliminate the noise of ethanol, a baseline correction was conducted before sample injection and measurement.

For HE staining, the mice were perfused with phosphate-buffered saline by cardiac perfusion techniques, and 4% PFA was used for tissue fixation. Sections of lungs (12 µm) were used for HE staining. The slides were treated at 60 °C for 30 min and then were rinsed with water. After washing, the slides were stained with hematoxylin for 3 min. After staining with hematoxylin, slides were washed sufficiently with water, immersed in 95% ethanol for 5 s, and counterstained with eosin for 10 s. The slides were dehydrated in a gradient concentration of ethanol and dehydrated with xylene for 3--5 min each. Finally, the slides were mounted with neutral balsam.

Genetic Association Analysis
----------------------------

The genetic association analysis of three key physiological traits, including hemoglobin level, pulmonary arterial pressure and degree of blood oxygen saturation, was performed using PLINK 1.07 ([@msw280-B34]). Based on the *EPAS1* expression analysis of endothelial cells and placentas, we adopted the additive genetic model in the association analysis. Gender and age were treated as covariates when applicable. For multiple test correction, we used a permutation test (100,000 times for each test) to generate empirical *P* values.

Statistical Analysis and Plot
-----------------------------

Unless specified, all statistical analyses were performed using R (<https://www.R-project.org>). Multiple test correction was performed using the Benjamini--Hochberg approach ([@msw280-B4]).
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